Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome

American Heart Journal

Volumn 162, Issue 4, 2011, Pages

  O'Donoghue, Michelle L ^a   Braunwald, Eugene ^a   White, Harvey D ^b   Serruys, Patrick ^d   Steg, Ph Gabriel ^e   Hochman, Judith ^f   Maggioni, Aldo P ^g   Bode, Christoph ^h   Weaver, Douglas ⁱ   Johnson, Joel L ^c   Cicconetti, Greg ^c   Lukas, Mary Ann ^c   Tarka, Elizabeth ^c   Cannon, Christopher P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c GLAXOSMITHKLINE   (United States)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^e BICHAT HOSPITAL   (France)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g ANMCO RESEARCH CENTER   (Italy)

^h UNIVERSITY OF FREIBURG   (Germany)

ⁱ HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 3A4; DARAPLADIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; ENTERIC COATED TABLET; ENZYME ACTIVITY; ENZYME INHIBITION; FECES ODOR; FOLLOW UP; HALITOSIS; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; METHODOLOGY; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; SKIN ODOR; STROKE; TREATMENT CONTRAINDICATION; TREATMENT DURATION; URINE ODOR;

EID: 80053647826     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2011.07.018     Document Type: Article

References (21)

1. P. Libby Inflammation in atherosclerosis Nature 420 2002 868 874 (Pubitemid 36019640)
2. D.M. Stafforini, M.R. Elstad, and T.M. McIntyre Human macrophages secret platelet-activating factor acetylhydrolase J Biol Chem 265 1990 9682 9687
3. K. Asano, S. Okamoto, and K. Fukunaga Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma Biochem Biophys Res Commun 261 1999 511 514 (Pubitemid 29392507)
4. 2 activity is a marker of small, dense LDL particles in human plasma Clin Chem 51 2005 2264 2273 (Pubitemid 41692569)
5. A. Thompson, P. Gao, and L. Orfei Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies Lancet 375 2010 1536 1544
6. 2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor Biochem J 338 Pt 2 1999 479 487
7. S.A. Karabina, M. Elisaf, and E. Bairaktari Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia Eur J Clin Invest 27 1997 595 602 (Pubitemid 27320037)
8. C.C. Hsieh, M.H. Yen, and H.W. Liu Lysophosphatidylcholine induces apoptotic and non-apoptotic death in vascular smooth muscle cells: in comparison with oxidized LDL Atherosclerosis 151 2000 481 491
9. M. Takahashi, H. Okazaki, and Y. Ogata Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism Atherosclerosis 161 2002 387 394 (Pubitemid 34219192)
10. T. Hakkinen, J.S. Luoma, and M.O. Hiltunen Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions Arterioscler Thromb Vasc Biol 19 1999 2909 2917 (Pubitemid 30029817)
11. 2 is highly expressed in macrophages of coronary lesions prone to rupture Circulation 110 2004 246 247
12. 2 reduces complex coronary atherosclerotic plaque development Nat Med 14 2008 1059 1066
13. Y. Jang, D. Waterworth, and J.E. Lee Carriage of the V279F null allele within the gene encoding Lp-PLA2 is protective from coronary artery disease in South Korean males PLoS ONE 6 2011 e18208
14. 2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study J Am Coll Cardiol 51 2008 1632 1641 (Pubitemid 351635837)
15. 2 activity, an emerging risk marker, can be inhibited in atherosclerotic lesions and plasma by novel pharmacologic intervention: the results of a multicenter clinical study Circulation 110 2004 III 590
16. P.W. Serruys, H.M. Garcia-Garcia, and P. Buszman Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque Circulation 118 2008 1172 1182
17. G.W. Stone, A. Maehara, and A.J. Lansky A prospective natural-history study of coronary atherosclerosis N Engl J Med 364 2011 226 235
18. H. White, C. Held, and R. Stewart Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease Am Heart J 160 2010 655 661
19. J.L. Anderson, C.D. Adams, and E.M. Antman ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction-executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J Am Coll Cardiol 50 2007 652 726
20. F.G. Kushner, M. Hand, and S.C. Smith Jr. Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 120 2009 2271 2306
21. K. Thygesen, J.S. Alpert, and H.D. White Universal definition of myocardial infarction Circulation 116 2007 2634 2653 (Pubitemid 350182388)